<unk>  is an inhibitor of vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and RET tyrosine kinases. RET tyrosine kinases; it weakly inhibits VEGFR-3. Metabolites of<unk>  (top left): N-desmethylvandetanib (bottom left, via CYP3A4),<unk> -N-oxide (bottom right, via FMO1 and FMO3), both pharmacologically active, and a minor amount of a glucuronide.<unk>  is well absorbed from the gut, reaches peak blood plasma concentrations 4 to 10 hours after application, and has a half-life of 19 days on average, per pharmacokinetic studies. It has to be taken for about three months to achieve a steady-state concentration. In the blood, it is almost completely (90–96%) bound to plasma proteins such as albumin. It is metabolised to N-desmethylvandetanib via CYP3A4 and to<unk> -N-oxide via FMO1 and 3. Both of these are active metabolites.<unk>  is excreted via the faeces (44%) and the urine (25%) in form of the unchanged drug and the metabolites.
Vandetanib
Selepressin
Masitinib
Vatalanib
Alectinib
Pegaptanib
Enasidenib
Tivozanib